HYPERHEP B

This brand name is authorized in Canada, Hong Kong, Israel, New Zealand, Singapore, Turkey, United States

Active ingredients

The drug HYPERHEP B contains one active pharmaceutical ingredient (API):

1 Human hepatitis B immunoglobulin UNII XII270YC6M - HUMAN HEPATITIS B VIRUS IMMUNE GLOBULIN

Human hepatitis B immunoglobulin solution for infusion contains mainly immunoglobulin G (IgG) with a specifically high content of antibodies against hepatitis B virus surface antigen (HBs). It is used for the immunoprophylaxis of hepatitis B and the prevention of hepatitis B virus re-infection after liver transplantation for hepatitis B induced liver failure. Read about Human hepatitis B immunoglobulin

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
HYPERHEP B Solution for injection	FDA, National Drug Code (US)	MPI, US: SPL/Old

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J06BB04	Hepatitis B immunoglobulin	J Antiinfectives for systemic use → J06 Immune sera and immunoglobulins → J06B Immunoglobulins → J06BB Specific immunoglobulins
Discover more medicines within J06BB04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: CA	Health Products and Food Branch	Identifier(s): 02230738, 02379465
Country: HK	Department of Health Drug Office	Identifier(s): 54263
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 8931, 8932
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 7718
Country: SG	Health Sciences Authority	Identifier(s): 09669P, 13490P, 13491P
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699769980160, 8699769980177, 8699769980184
Country: US	FDA, National Drug Code	Identifier(s): 13533-636